Pfizer and
GSK have been continuously decreasing their stakes in
Haleon, generating billions in capital through shares sales. This led to a series of soaring and falling in Haleon's share price, with decisions to drop stakes being influenced by a myriad of factors. Furthermore, Quarter 1 of 2024 showed Haleon's
financial performance and results, which were a mixed bag. The earnings results showed satisfactory performance but glimpses of future pressures, leading some investors to speculate future performance. Despite revenue misses, the
EPS managed to surpass expectations. Moreover, there are
rumours of planned layoffs and potential securities offering, further heating up the speculation around Haleon. Amidst this buzz, Haleon announced a
share buyback program, leading to a surge in share price. Notably, Haleon successfully managed to clinch several
major share buyback deals with Pfizer. The mixed financial revelations and significant stakeholders' moves certainly influenced Haleon's market position in recent times.
Haleon Stocks News Analytics from Thu, 13 Jul 2023 07:00:00 GMT to Thu, 23 May 2024 16:27:33 GMT -
Rating 5
- Innovation -2
- Information 7
- Rumor 3
